All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Neonatal jaundice is a common condition affecting over 60% of neonates, and frequently requiring medical attention \[[@pone.0205432.ref001]\]. While usually benign, sustained elevated bilirubin levels can occasionally result in permanent neurological damage or death, but these outcomes can be prevented through appropriate management. This has been largely, but not entirely, achieved in high-resource settings \[[@pone.0205432.ref002], [@pone.0205432.ref003]\].

In low resource settings (LRSs), treatment of neonatal jaundice is often sub-optimal \[[@pone.0205432.ref004], [@pone.0205432.ref005]\]. Conventional fluorescent light phototherapy is often the only available option in LRSs, and the irradiance provided is usually below recommended levels \[[@pone.0205432.ref006]--[@pone.0205432.ref008]\]. Common reasons for low irradiance include: using white fluorescent bulbs with low irradiance in the efficacious spectrum for treatment of jaundice; and failure to replace blue bulbs on a regular basis (typically 1,000--2,000 hours) due to cost, lack of a photo radiometer to monitor irradiance, or lack of an on-machine counter to track hours of use. Sub-optimal phototherapy treatment can lead to long lengths of stay while jaundice resolves spontaneously, and the lack of effective phototherapy can lead to a need for exchange transfusion \[[@pone.0205432.ref008]\]; both outcomes pose additional risks to neonates, and have resource implications for facilities caring for sick neonates in LRSs.

A Cochrane Review found that LED and non-LED (halogen or fluorescent bulb) phototherapy result in a comparable rate of reduction of total serum bilirubin (TSB) \[[@pone.0205432.ref009]\]. The cost of LED phototherapy has reduced markedly in recent years, and LED phototherapy bulbs typically have a 40,000--50,000 hour lifespan, eliminating the need for frequent replacement of bulbs, making it an affordable technology for LRSs and creating the opportunity for high quality phototherapy to be consistently provided in LRS.

The aim of the present study was to compare three different LED machines, two single-sided and one double-sided, in speed of reduction of TSB, duration of treatment with phototherapy, and total length of stay (LOS). The study was undertaken as part of a program of operational research to inform programming decisions by an international non-government organization (INGO) that donates LED phototherapy to hospitals in LRSs.

Materials and methods {#sec006}
=====================

Setting {#sec007}
-------

The Da Nang Hospital for Women and Children, located in south-central Viet Nam, had 13,411 births in 2014 and its Neonatal Care Unit (NCU) accepted 3,934 admissions, born at the hospital or transferred in, of which 1,207 (30.7%) were for jaundice. The hospital had several LED and conventional phototherapy machines prior to study commencement. Neonates were enrolled in the study from May 2013 to September 2014.

Study population {#sec008}
----------------

The study population was restricted to infants born weighing ≥1500g, with jaundice diagnosed visually or by TSB, and having their first episode of phototherapy at the hospital. Infants with gestational age \<33 weeks, those with axillary temperature \<36.5°C or \>37.5°C at treatment commencement and those treated in an incubator were excluded.

Intervention {#sec009}
------------

The study compared three LED phototherapy machines specifically designed for LRSs ([Table 1](#pone.0205432.t001){ref-type="table"}). Two machines provide single-sided phototherapy from above ("PTV3000" and "Lullaby"), while the third ("Firefly") is double-sided. The lamp heads of both single-sided machines can be adjusted to provide therapy at various distances from the baby, altering the irradiance, while the double-sided device provides treatment at a fixed distance from both above and below. The Firefly has a single irradiance setting while both single-sided machines have two settings and can be put into high-irradiance mode by flicking a switch; the PTV3000 automatically reverts to standard mode after 3 hours, while the Lullaby must be manually switched back. No restrictions were placed on the hospital's use of the single-sided machines, in relation to the distance of the lights from the neonate, or the irradiance setting to be used.

10.1371/journal.pone.0205432.t001

###### Key features of the three LED phototherapy machines.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               PTV3000                                                           Lullaby                                                                Firefly
  ------------------------------------------------------------ ----------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------
  Weight                                                       18.4 kg                                                           10 kg                                                                  13 kg

  Irradiance settings                                          Two: Standard/High\                                               Two: Standard/High\                                                    Single setting
                                                               \[High setting reverts to low automatically after 3 hours use\]   \[High setting is changed by manually flicking a switch\]              

  Fixed/adjustable treatment distance                          Adjustable                                                        Adjustable (and head is detachable allowing place atop an incubator)   Fixed

  Irradiance from above[\*](#t001fn001){ref-type="table-fn"}   Standard: 25 μW/nm/cm^2^\                                         Standard: 22 μW/nm/cm^2^\                                              32 μW/nm/cm^2^\
                                                               High: 40 μW/nm/cm^2^\                                             High: 45 μW/nm/cm^2^\                                                  \[Fixed distance\]
                                                               \[Measured at 40 cm\]                                             \[Measured at 35 cm\]                                                  

  Irradiance from below[\*](#t001fn001){ref-type="table-fn"}   N/A                                                               N/A                                                                    36 μW/nm/cm^2^\
                                                                                                                                                                                                        \[Fixed distance\]

  LED bulb type\                                               Luxeon Rebel Royal Blue, High Power\                              Cree\                                                                  Seoul Semiconductor Blue High Power\
  \[dominant wavelength\]                                      \[450--475 nm\]                                                   \[450--465 nm\]                                                        \[453--465 nm\]

  Number of bulbs                                              42                                                                10                                                                     10 above + 18 below

  Expected bulb life[^\#^](#t001fn002){ref-type="table-fn"}    50,000                                                            50,000                                                                 44,000
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* As per manufacturer's specification.

^\#^ Estimated hours of use before reaching 70% lumen maintenance (i.e., 30% reduction in irradiance)

Allocation {#sec010}
----------

While the study was observational, an un-blinded system of quasi-randomisation was devised. As the NCU had limited space, only one machine of each type was provided for the study, and it would have prolonged the study if infants could only be allocated when all three machines were available. Eligible infants were allocated in a standard order, based on a number assigned to each device: the PTV3000 was assigned \#1, the Lullaby \#2 and the Firefly \#3. Allocation was to the available machine where only one was available, or to the lower numbered machine if two or more were available.

Data {#sec011}
----

To minimise the data collection burden, no data was collected on eligible babies that were excluded for any reason. For enrolled infants, data was collected on several factors including: estimated gestational age; birthweight, date and time of birth; inborn/outborn status; sex; maternal and infant blood type and direct Coomb's test; Rh(D) status; G6PD deficiency; previous sibling received phototherapy; significant bruising; exclusive breastfeeding and feeding poorly; date and time and TSB (μmol/L) at treatment start and at end, and TSB at 6 hours; date and time of nursery admission and discharge; selected treatments that could influence length of stay (oxygen; antibiotics); machine allocation; and machine used for treatment. Data was collected by hospital clinicians on individual paper forms, and forwarded to project staff for entry in a database.

Endpoints {#sec012}
---------

The primary endpoint was change in TSB/hour, over the first six hours of treatment, to provide information about the relative efficacy of the machines with minimal opportunity for confounding. The secondary endpoints were: duration of phototherapy; change in TSB/hour over the whole duration of treatment; and LOS in the NCU. For each endpoint, a comparison of the three phototherapy machines and by a comparison of single vs. double sided machines were performed.

Power {#sec013}
-----

The power of the study was based on a planned recruitment of 300 infants. Because of the unbalanced allocation built into the design, it was noted that the Firefly would have the lowest number of infants. Means and standard deviations were unknown; allocation of 63 infants per group allowed detection of a difference of half a standard deviation in pairwise means; by enrolling 300 infants, we anticipated ≥ 63 infants in all three groups, and capacity to detect this difference or more.

Statistical analysis {#sec014}
--------------------

Categorical data were expressed as number and percentage, while continuous data as median and interquartile range (IQR). Demographics and risk factors for hyperbilirubinemia were compared among the three phototherapy groups using Fisher's Exact test or Kruskal-Wallis test, as appropriate. Multivariable analysis of primary and secondary endpoints was performed using ordinary least squares (OLS) regression, adjusting for potential confounders that were reported in 10 or more infants. As the distributions were only approximately normal, statistical significance was confirmed using bootstrap methods to calculate 95% Confidence Intervals (CIs), which were compared to CIs produced by OLS. Sampling for bootstrap analysis was with replacement, undertaken within each allocation group to create 10,000 samples of the same size and treatment group composition as the original; the final OLS model was re-run on each of the samples and parameter estimates saved; for each of the parameters estimated, the mean of each parameter was calculated, and the 2.5th and 97.5th percentile were used as the bounds of the bootstrap 95% CIs \[[@pone.0205432.ref010]\]. The average change in endpoint was calculated using OLS parameter estimates and the mean value or prevalence for each potential confounder. The duration outcomes (duration of treatment and LOS in the NCU) were positively skewed, thus were log-transformed before analysis. Since the transformed outcomes did not meaningfully improve model fit or alter the statistical significance, results of untransformed models were reported to ease interpretation of results. Analysis was based on the principle of 'intention to treat' and included a comparison of the three phototherapy machines, followed by a comparison of single vs. double sided machines. All tests were two-tailed and analysis was performed using SAS 9.4 (SAS Institute, Cary, NC).

Ethical approval {#sec015}
----------------

The Ethics Committee at the Da Nang Hospital for Women and Children approved the study and waived the need for consent given the observational design of the study.

Results {#sec016}
=======

Patients {#sec017}
--------

At study completion, 310 infants had been allocated to the three machines: 113 to the PTV3000, 104 to the Lullaby, and 93 to the Firefly. All infants were treated on the machines to which they were assigned; 26% commenced treatment \<72 hours of age, and 25% commenced treatment \>120 hours of age. Median TSB at the start of treatment was 287 μmol/L (IQR 255--328). Patient characteristics are shown in [Table 2](#pone.0205432.t002){ref-type="table"}. Infants allocated to Firefly were less likely to commence treatment \<72 hours of age (p\<0.05) and had higher median TSB at start of treatment (p\<0.001). No infant was: Rh(D) positive; born to a multiparous Rh(D) negative mother; having received oxygen; having a previous sibling who received phototherapy; having significant bruising; or breastfeeding exclusively and feeding poorly.

10.1371/journal.pone.0205432.t002

###### Patient characteristics by treatment allocation.
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                                                        Total          Specific machine   Machine type                                                       
  -------------------------------------- -------------- -------------- ------------------ -------------- -------------- ----------- ------------ ----------- ---------
  n                                                     310            113                104            93                         217          93           
  Place of birth                         Inborn         247 (79.7)     92 (81.4)          83 (79.8)      72 (77.4)      0.70        175 (80.7)   72 (77.4)   0.42
  Outborn                                57 (18.4)      19 (16.8)      18 (17.3)          20 (21.5)      37 (17.1)      20 (21.5)                            
  Missing                                6 (1.9)        2 (1.8)        3 (2.9)            1 (1.1)        5 (2.3)        1 (1.1)                              
  Sex                                    Male           183 (59.0)     59 (52.2)          63 (60.6)      61 (65.6)      0.14        122 (56.2)   61 (65.6)   0.17
  Female                                 126 (40.6)     54 (47.8)      40 (38.5)          32 (34.4)      94 (43.3)      32 (34.4)                            
  Missing                                1 (0.3)        0 (0.0)        1 (1.0)            0 (0.0)        1 (0.5)        0 (0.0)                              
  Birthweight,                           Grams          3100           3170               3100           3109           0.44        3100         3109        0.60
  (2840--3400)                           (2900--3400)   (2800--3355)   (2900--3400)       (2800--3400)   (2900--3400)                                        
  35--38 weeks gestation                 No             209 (67.4)     82 (72.6)          69 (66.3)      58 (62.4)      0.31        151 (69.6)   58 (62.4)   0.19
  Yes                                    99 (31.9)      31 (27.4)      33 (31.7)          35 (37.6)      64 (29.5)      35 (37.6)                            
  Missing                                2 (0.6)        0 (0.0)        2 (1.9)            0 (0.0)        2 (0.9)        0 (0.0)                              
  G6PD                                   Not tested     298 (96.1)     109 (96.5)         101 (97.1)     88 (94.6)      0.55        210 (96.8)   88 (94.6)   0.52
  Sufficiency                            9 (2.9)        4 (3.5)        2 (1.9)            3 (3.2)        6 (2.7)        3 (3.2)                              
  Deficiency                             3 (1.0)        0 (0.0)        1 (1.0)            2 (2.2)        1 (0.5)        2 (2.2)                              
  ABO (Coombs +ve)                       Not tested     9 (2.9)        3 (2.6)            6 (5.8)        0 (0.0)        0.75        9 (4.2)      0 (0.0)     0.51
  Negative                               299 (96.5)     109 (96.5)     98 (94.2)          92 (98.9)      209 (96.3)     92 (98.9)                            
  Positive                               2 (0.6)        1 (0.9)        0 (0.0)            1 (1.1)        1 (0.5)        1 (1.1)                              
  Infection (treated with antibiotics)   No             272 (87.7)     95 (84.1)          93 (89.4)      84 (90.3)      0.33        188 (86.6)   84 (90.3)   0.45
  Yes                                    38 (12.3)      18 (15.9)      11 (10.6)          9 (9.7)        11 (13.4)      9 (9.7)                              
  TSB at start of treatment              μmol/L         287            277                276            308            \<0.001     277          308         \<0.001
  (255--328)                             (255--327)     (250--301)     (275--346)         (253--317)     (275--346)                                          
  Age at start of treatment              \<72 hours     80 (25.8)      35 (31.0)          30 (28.9)      15 (16.1)      0.04        65 (29.9)    15 (16.1)   0.01
  72--120 hours                          137 (44.2)     44 (38.9)      41 (39.4)          52 (55.9)      85 (39.2)      52 (55.9)                            
  \>120 hours                            77 (24.8)      28 (24.8)      28 (26.9)          21 (22.6)      56 (25.8)      21 (22.6)                            
  Missing                                16 (5.2)       6 (5.3)        5 (4.8)            5 (5.4)        11 (5.1)       5 (5.4)                              

Data expressed as n (%) or median (IQR). Comparisons were performed excluding missing data.

Primary outcome {#sec018}
---------------

Over first six hours, Firefly lowered the TSB faster than PTV3000 (mean difference 1.51 μmol/L, 95% CI -2.56 to -0.45), while TSB decrease was similar with Lullaby and PTV3000 (mean difference 0.48 μmol/L, 95% CI -1.54 to 0.58) ([Table 3](#pone.0205432.t003){ref-type="table"}). These findings were confirmed in double- vs. single-sided comparison (mean difference -1.29 μmol/L, 95% CI -2.34 to -0.26) ([Table 3](#pone.0205432.t003){ref-type="table"}). OLS and bootstrap analyses showed comparable estimates.

10.1371/journal.pone.0205432.t003

###### Change in TSB per hour (μmol/L) over first six hours.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                               Univariate analysis      Multivariable analysis                                                     
  ------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------
  Intercept                                                           Intercept                Various                  -2.04 (-6.47 to 2.38)    -2.04 (-6.05 to 2.22)    -2.41 (-6.77 to 1.95)    -2.39 (-6.57 to 1.88)

  Machine [^\#^](#t003fn002){ref-type="table-fn"}                     PTV3000                  Ref                      Ref                      Ref                      \-                       \-

  Lullaby                                                             -0.18 (-1.34 to 0.97)    -0.50 (-1.55 to 0.55)    -0.48 (-1.54 to 0.58)                                                      

  Firefly                                                             -1.81 (-2.98 to -0.64)   -1.50 (-2.60 to -0.40)   -1.51 (-2.56 to -0.45)                                                     

  Machine type                                                        Single-sided             Ref                      \-                       \-                       Ref                      Ref

  Double-sided                                                        -1.72 (-2.76 to -0.69)   -1.27 (-2.26 to -0.28)   -1.29 (-2.34 to -0.26)                                                     

  Place born\                                                         Inborn                   Ref                      Ref                      Ref                      Ref                      Ref

  Outborn                                                             -0.80 (-2.08 to 0.48)    -0.20 (-1.40 to 0.99)    -0.20 (-1.56 to 1.13)    -0.22 (-1.41 to 0.97)    -0.20 (-1.65 to 1.15)    

  Birthweight                                                         kg                       2.01 (0.79 to 3.23)      2.42 (1.27 to 3.57)      2.42 (1.09 to 3.75)      2.43 (1.28 to 3.58)      2.43 (1.03 to 3.77)

  Sex                                                                 Female                   Ref                      Ref                      Ref                      Ref                      Ref

  Male                                                                0.39 (-0.59 to 1.38)     0.15 (-0.76 to 1.05)     0.15 (-0.77 to 1.07)     0.13 (-0.78 to 1.03)     0.13 (-0.80 to 1.06)     

  35--38 weeks\                                                       No                       Ref                      Ref                      Ref                      Ref                      Ref

  Yes                                                                 0.74 (-0.29 to 1.77)     0.92 (-0.04 to 1.89)     0.92 (0.002 to 1.81)     0.92 (-0.05 to 1.88)     0.91 (-0.01 to 1.93)     

  Infection treated with antibiotics                                  No                       Ref                      Ref                      Ref                      Ref                      Ref

  Yes                                                                 -1.55 (-3.00 to -0.11)   -2.04 (-3.42 to -0.66)   -2.03 (-3.58 to -0.55)   -1.99 (-3.36 to -0.62)   -1.98 (-3.48 to -0.54)   

  Age at start of phototherapy[\^](#t003fn003){ref-type="table-fn"}   \<72 hours               -0.30 (-1.46 to 0.85)    -0.26 (-0.88 to 1.39)    -0.25 (-0.80 to 1.32)    -0.26 (-0.88 to 1.39)    -0.25 (-0.83 to 1.32)

  72--120 hours                                                       Ref                      Ref                      Ref                      Ref                      Ref                      

  \>120 hours                                                         -1.81 (-2.99 to -0.64)   -1.00 (-2.15 to 0.15)    -1.00 (-2.15 to -0.14)   -1.01 (-2.16 to 0.13)    -1.02 (-2.15 to 0.11)    

  TSB at start of phototherapy                                        /100 μmol/L              -2.81 (-3.66 to -1.96)   -2.56 (-3.43 to -1.69)   -2.56 (-3.78 to -1.35)   -2.52 (-3.39 to -1.66)   -2.52 (-3.70 to -1.35)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OLS: Ordinary Least Squares Regression. Pt. Est.: Point Estimate. 95% CI: 95% Confidence Interval.

^\#^ Overall p-values for overall machine effect: univariate: p = 005; multivariable: p = 0.03.

\^ Overall p-values for overall effect of age at start of treatment: univariate: p = 009; multivariable three-machine: p = 0.13; multivariable: p = 0.12.

Secondary outcomes {#sec019}
------------------

As with the primary endpoint, the two single-sided machines (Lullaby than PTV3000) showed comparable results regarding the secondary endpoints (Tables [4](#pone.0205432.t004){ref-type="table"}--[6](#pone.0205432.t006){ref-type="table"}). Double-sided phototherapy was associated with a 13.8-hour reduction in the duration of treatment (95% CI 5.7 to 22.8; [Table 4](#pone.0205432.t004){ref-type="table"}). The average duration of treatment was 64.7 hours on single-sided phototherapy and 50.9 hours on double-sided, which represents a 21% reduction in treatment duration. More than half of all phototherapy treatments ceased on the hour, between 7--11 am, likely reflecting clinical schedules for patient review.

10.1371/journal.pone.0205432.t004

###### Duration of phototherapy (hours).
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              Univariate analysis     Multivariable analysis                                                
  ------------------------------------------------------------------- ----------------------- ----------------------- ------------------------ ---------------------- --------------------- ----------------------
  Intercept                                                           Intercept               Various                 3.0 (-35.2 to 41.2)      2.9 (-33.2 to 37.6)    2.2 (-35.4 to 39.7)   2.3 (-33.0 to 36.7)

  Machine [^\#^](#t004fn002){ref-type="table-fn"}                     PTV3000                 Ref                     Ref                      Ref                    \-                    \-

  Lullaby                                                             -4.5 (-14.1 to 5.1)     -1.1 (-10.1 to 7.9)     -1.0 (-10.7 to 8.2)                                                   

  Firefly                                                             -11.2 (-21.0 to -1.4)   -14.3 (-23.7 to -4.8)   -14.1 (-25.8 to -3.9)                                                 

  Machine type                                                        Single-sided            Ref                     \-                       \-                     Ref                   Ref

  Double-sided                                                        -9.1 (-17.8 to -0.4)    -13.8 (-22.3 to -5.3)   -13.8 (-22.8 to -5.7)                                                 

  Place born\                                                         Inborn                  Ref                     Ref                      Ref                    Ref                   Ref

  Outborn                                                             -1.3 (-11.9 to 9.3)     -5.3 (-15.6 to 5.0)     -5.2 (-15.2 to 4.3)      -5.3 (-15.6 to 4.9)    -5.3 (-15.4 to 4.4)   

  Birthweight                                                         kg                      4.0 (-14.3 to 6.2)      -1.9 (-11.8 to 8.1)      -1.7 (-16.0 to 10.5)   -1.8 (-11.8 to 8.1)   -1.8 (-16.1 to 10.4)

  Sex                                                                 Female                  Ref                     Ref                      Ref                    Ref                   Ref

  Male                                                                -6.0 (-14.1 to 2.1)     -3.2 (-11.0 to 4.6)     -3.3 (-10.3 to 4.3)      -3.2 (-11.0 to 4.6)    -3.3 (-10.4 to 4.2)   

  35--38 weeks                                                        No                      Ref                     Ref                      Ref                    Ref                   Ref

  Yes                                                                 4.9 (-3.7 to 13.4)      9.6 (1.2 to 17.9)       9.3 (0.4 to 19.3)        9.5 (1.2 to 17.8)      9.4 (0.6 to 19.4)     

  Infection treated with antibiotics                                  No                      Ref                     Ref                      Ref                    Ref                   Ref

  Yes                                                                 20.0 (8.2 to 31.8)      20.4 (8.5 to 32.3)      20.5 (8.5 to 32.2)       20.5 (8.7 to 32.3)     20.5 (8.7 to 32.4)    

  Age at start of phototherapy[\^](#t004fn003){ref-type="table-fn"}   \<72 hours              9.6 (-0.1 to 19.2)      4.2 (-5.6 to 14.0)       4.1 (-4.0 to 12.6)     4.2 (-5.6 to 14.0)    4.1 (-4.0 to 12.8)

  72--120 hours                                                       Ref                     Ref                     Ref                      Ref                    Ref                   

  \>120 hours                                                         7.6 (-2.2 to 17.4)      3.7 (-6.2 to 13.6)      3.5 (-5.7 to 14.0)       3.7 (-6.2 to 13.5)     3.7 (-5.7 to 14.1)    

  TSB at start of phototherapy                                        /100 μmol/L             17.1 (9.8 to 24.3)      21.4 (13.9 to 28.9)      21.2 (11.5 to 32.6)    21.5 (14.0 to 28.9)   21.4 (11.4 to 33.7)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OLS: Ordinary Least Squares Regression. Pt. Est.: Point Estimate. 95% CI: 95% Confidence Interval.

^\#^ Overall p-values for overall machine effect: univariate: p = 0.08; multivariable: p = 0.007

\^ Overall p-values for overall effect of age at start of treatment: univariate: p = 0.10; multivariable three-machine: p = 0.63; multivariable: p = 0.63.

10.1371/journal.pone.0205432.t005

###### Change in TSB per hour (μmol/L) over treatment.
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                                                                                             Univariate analysis    Multivariable analysis                                                 
  ------------------------------------------------------------------- ---------------------- ---------------------- ------------------------ ---------------------- ---------------------- ----------------------
  Intercept                                                           Intercept              Various                -0.48 (-2.07, 1.10)      -0.49 (-2.00, 1.00)    -0.65 (-2.22, 0.93)    -0.66 (-2.21, 0.83)
  Machine [^\#^](#t005fn002){ref-type="table-fn"}                     PTV3000                Ref                    Ref                      Ref                    \-                     \-
  Lullaby                                                             -0.29 (-0.70, 0.11)    -0.28 (-0.66, 0.10)    -0.28 (-0.66, 0.07)                                                    
  Firefly                                                             -1.20 (-1.60, -0.79)   -1.08 (-1.48, -0.68)   -1.09 (-1.48, -0.73)                                                   
  Machine type                                                        Single-sided           Ref                    \-                       \-                     Ref                    Ref
  Double-sided                                                        -1.04 (-1.40, -0.70)   -0.94 (-1.29, -0.59)   -0.94 (-1.29, -0.62)                                                   
  Place born                                                          Inborn                 Ref                    Ref                      Ref                    Ref                    Ref
  Outborn                                                             -0.05 (-0.43, 0.52)    0.33 (-0.11, 0.76)     0.33 (-0.11, 0.76)       0.31 (-0.13, 0.75)     -0.31 (-0.12, 0.73)    
  Birthweight                                                         kg                     0.02 (-0.02, 0.4)      0.21 (-0.19, 0.61)       0.21 (-0.15, 0.60)     0.23 (-0.18, 0.63)     0.23 (-0.14, 0.62)
  Sex                                                                 Female                 Ref                    Ref                      Ref                    Ref                    Ref
  Male                                                                -0.11 (-0.47, 0.26)    -0.09 (-0.42, 0.24)    -0.09 (-0.42, 0.24)      -0.11 (-0.44, 0.21)    -0.11 (-0.45, 0.23)    
  35--38 weeks                                                        No                     Ref                    Ref                      Ref                    Ref                    Ref
  Yes                                                                 0.27 (-011, 0.66)      0.34 (-0.02, 0.69)     0.34 (0.03, 0.65)        0.32 (-0.03, 0.68)     0.32 (0.02, 0.63)      
  Infection treated with antibiotics                                  No                     Ref                    Ref                      Ref                    Ref                    Ref
  Yes                                                                 0.51 (-0.04, 1.07)     0.28 (-0.23, 0.80)     0.29 (-0.21, 0.79)       0.29 (-0.22, 0.80)     0.29 (-0.21, 0.79)     
  Age at start of phototherapy[\^](#t005fn003){ref-type="table-fn"}   \<72 hours             -0.16 (-0.26, 0.57)    -0.15 (-0.55, 0.24)      -0.16 (-0.60, 0.24)    -0.15 (-0.55, 0.24)    -0.15 (-0.61, 0.25)
  72--120 hours                                                       Ref                    Ref                    Ref                      Ref                    Ref                    
  \>120 hours                                                         -0.58 (-1.02, -0.15)   -0.59 (-1.00, -0.17)   -0.59 (-1.02, -0.18)     -0.60 (-1.01, -0.19)   -0.60 (-1.04, -0.18)   
  TSB at start of phototherapy                                        /100 μmol/L            -1.00 (-1.32, -0.69)   -0.69 (-1.02, -0.37)     -0.69 (-1.05, -0.31)   0.69 (-1.02, -0.37)    -0.69 (-1.05, -0.29)

OLS: Ordinary Least Squares Regression. Pt. Est.: Point Estimate. 95% CI: 95% Confidence Interval.

^\#^ Overall p-values for overall machine effect: univariate: p\<0.0001; multivariable: p\<0.0001

\^ Overall p-values for overall effect of age at start of treatment: univariate: p = 0.006; multivariable three-machine: p = 0.02; multivariable: p = 0.02

10.1371/journal.pone.0205432.t006

###### LOS in NCU (hours).
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                                                                                            Univariate analysis    Multivariable analysis                                             
  ------------------------------------------------------------------- --------------------- ---------------------- ------------------------ -------------------- -------------------- --------------------
  Intercept                                                           Intercept             Various                45.0 (-2.4, 92.4)        44.8 (-0.02, 90.3)   44.0 (-2.6, 90.7)    43.8 (0.8, 87.7)
  Machine [^\#^](#t006fn002){ref-type="table-fn"}                     PTV3000               Ref                    Ref                      Ref                  \-                   \-
  Lullaby                                                             -7.9 (-21.4, 5.5)     -1.4 (-12.6, 9.9)      -1.5 (-13.6, 10.8)                                                 
  Firefly                                                             -15.2 (-28.9, -1.6)   -14.6 (-26.4, -2.8)    -14.5 (-27.2, -2.9)                                                
  Machine type                                                        Single-sided          Ref                    \-                       \-                   Ref                  Ref
  Double-sided                                                        -11.5 (-23.7, 0.6)    -14.0 (-24.6, -3.4)    -13.7 (-24.7, -3.3)                                                
  Place born                                                          Inborn                Ref                    Ref                      Ref                  Ref                  Ref
  Outborn                                                             -0.2 (-15.0, 14.7)    -6.4 (-19.2, 6.4)      -6.5 (-20.7, 9.4)        -6.5 (-19.3, 6.3)    6.6 (-20.9, 9.4)     
  Birthweight                                                         kg                    -14.3 (-28.5, -0.02)   -10.8 (-23.1, 1.6)       -10.4 (-27.2, 4.5)   -10.7 (-23.0, 1.6)   -10.4 (-27.0, 4.7)
  Sex                                                                 Female                Ref                    Ref                      Ref                  Ref                  Ref
  Male                                                                -5.5 (-16.9, 5.9)     1.6 (-8.2, 11.3)       1.2 (-8.6, 12.1)         1.5 (-8.2, 11.2)     1.2 (-9.0, 11.9)     
  35--38 weeks                                                        No                    Ref                    Ref                      Ref                  Ref                  Ref
  Yes                                                                 0.5 (-12.5, 11.5)     3.5 (-6.9, 13.9)       3.4 (-7.4, 14.3)         3.5 (-6.9, 13.9)     3.4 (-7.4, 14.6)     
  Infection treated with antibiotics                                  No                    Ref                    Ref                      Ref                  Ref                  Ref
  Yes                                                                 74.0 (60.4, 89.1)     76.2 (61.4, 91.0)      76.3 (55.7, 99.4)        76.3 (61.6, 91.0)    76.2 (55.9, 99.1)    
  Age at start of phototherapy[\^](#t006fn003){ref-type="table-fn"}   \<72 hours            21.5 (8.1, 34.9)       2.0 (-10.2, 14.2)        1.9 (-8.9, 13.2)     2.0 (-10.2, 14.2)    1.9 (-8.6, 12.9)
  72--120 hours                                                       Ref                   Ref                    Ref                      Ref                  Ref                  
  \>120 hours                                                         9.3 (-4.2, 22.8)      5.9 (-6.4, 18.2)       5.8 (-7.0, 18.7)         5.9 (-6.4, 18.2)     5.8 (-7.0, 18.8)     
  TSB at start of phototherapy                                        /100 μmol/L           15.0 (46.1, 25.3)      21.6 (12.3, 30.9)        21.4 (8.3, 35.8)     21.7 (12.5, 31.0)    21.5 (8.3, 35.9)

OLS: Ordinary Least Squares Regression. Pt. Est.: Point Estimate. 95% CI: 95% Confidence Interval.

\# Overall p-values for overall machine effect: univariate: p = 0.09; multivariable: p = 0.03

\^ Overall p-values for overall effect of age at start of treatment: univariate: p = 0.007; multivariable three-machine: p = 0.64; multivariable: p = 0.64.

Double-sided phototherapy resulted in TSB reduction at a rate 0.94 μmol/L/hr faster (95% CI 0.62 to 1.29) than single-sided over the whole duration of treatment ([Table 5](#pone.0205432.t005){ref-type="table"}). The average rate of TSB reduction was 2.1 μmol/L/hr on the single-sided phototherapy and 3.0 μmol/L/hr on the double-sided, representing a 45% increase in the rate of TSB reduction over the whole duration of treatment.

Double-sided phototherapy resulted in a 14-hour shorter LOS in the NCU (95% CI 3 to 25; [Table 6](#pone.0205432.t006){ref-type="table"}). The average LOS in the NCU for this study population was 87 hours on single-sided phototherapy and 73 hours on double-sided, representing a 16% reduction in LOS. OLS and bootstrap analyses showed comparable estimates. The time of discharge from the NCU showed a likely practice schedule: 88% of discharges from the unit were at 7, 8 or 11am, or at 2 or 5 pm.

Discussion {#sec020}
==========

Neonatal jaundice is one of the most common conditions requiring hospital admission \[[@pone.0205432.ref001]\], and has been reported to be responsible for half of admissions to NCUs in some LRSs \[[@pone.0205432.ref008]\]. Prevention, accurate diagnosis and effective treatment are all important elements of jaundice management \[[@pone.0205432.ref011]\]. This study focused on effective treatment and compared different LED phototherapy machines designed for use in LRSs in term of speed of TSB reduction and duration of treatment. Speed of TSB reduction is important in preventing higher-risk interventions such as exchange transfusion, while duration of treatment and LOS impact workload in NCUs and the number of infants that can potentially benefit from treatment.

After adjusting for TSB at the start of treatment, and other potential confounders, the two single-sided machines (PTV3000 and Lullaby) showed no difference in the speed of TSB reduction, in duration of treatment and in LOS in the NCU.

Increasing the surface-area exposed to light has been routinely recommended for improving the effectiveness of phototherapy \[[@pone.0205432.ref012]--[@pone.0205432.ref014]\]. Several studies compared single- and double-sided phototherapy to increase surface area, with conflicting results. Some reported faster speed of reduction and/or shorter duration of treatment with double-sided treatment \[[@pone.0205432.ref015]--[@pone.0205432.ref020]\], but others showed no difference in a simple comparison \[[@pone.0205432.ref021]\]. or where the total irradiance was identical in the single or double-sided configurations \[[@pone.0205432.ref022]\], or where single-sided therapy was augmented with reflecting curtains \[[@pone.0205432.ref023]\].

Here we assessed, for first the first time, the effectiveness on TSB reduction of a single- vs double-sided LED phototherapy machines specifically designed for use in LRSs; robust and simple to use. After controlling for potential confounders, the double-sided machine had a rate of TSB reduction which was 54% faster in the first 6 hours of treatment, and 45% faster over the duration of treatment. After adjustment, double-sided treatment was also associated with an 14-hour reduction in the duration of treatment, and a 14-hour reduction in LOS in the NCU. It is notable that the PTV3000 has white curtains and a method of fixing them in place, and clinicians confirm that these curtains were routinely used during treatment. However, consistent differences were still found between PTV3000 and the double-sided Firefly in speed of TSB reduction, and in duration of treatment and LOS.

From a planning point of view, a combination of different types of phototherapy devices in an NCU is likely to be optimal, depending on the funds available and cost of the machines. An increasing number of different LED phototherapy machines are being developed for use in LRSs, but the cost and availability of any particular machine can vary enormously from one LRS to another. Where available and affordable, replacing conventional phototherapy with LED can solve the problem of ineffective phototherapy being provided in LRSs, reducing ongoing administrative and financing costs associated with the supply of replaceable bulbs. For infants that can thermoregulate, and in settings where ambient temperature is adequate, double-sided Firefly can lead to faster reduction in TSB, a shorter duration of treatment and a shorter LOS in the NCU.

Given the known and potential side-effects associated with phototherapy \[[@pone.0205432.ref024]\], clinical schedules which optimise treatment durations are justified. In the current study, all TSB testing was conducted in the hospital laboratory, with longer delays expected for TSB results requested at night, or on weekends. The availability of affordable and reliable TSB testing within the NCU, to determine whether it is appropriate to cease treatment, could help modify these schedules \[[@pone.0205432.ref025]\], In addition, we noted a strong preference for phototherapy to end at 7--11 am, implying that treatment may be continuing longer than required, to fit clinical schedules. Similarly, we identified a practice pattern for infants to be discharged at particular times of the day. If confirmed, more frequent clinical review could result in shorter treatment duration and shorter LOS. Moreover, given the overcrowding found in many NCUs in LRSs, and the associated exposure to nosocomial infection, more frequent NCU-discharge review of lower risk neonates could help decongest NCUs by ensuring that infants only stay as long as necessary. Once again, availability of affordable and reliable TSB testing within the NCU could facilitate this, by proving prompt assessments of TSB rebound.

Beyond the comparisons in this paper, it should be noted that other options are available for treatment of jaundice in LRSs, including promising results with UV-filtered sunlight to treat infant with TSB \<257 μmol/L \[[@pone.0205432.ref026], [@pone.0205432.ref027]\]. For infants with higher TSB requiring rapid TSB reduction, it is common for clinicians to use multiple machine simultaneously, where available.

This study has some limitations. First, because the Firefly cannot be used with an overhead heater, or within an incubator, the results can only be generalised to environments that allow for treatment without personalised heating, and to infants that can thermoregulate within that environment. While exclusion criteria were set lower, the study only enrolled infants born at ≥35 weeks' gestation, weighing ≥1,900g, so results can only be generalised to this population. To minimise workload, we did not collect data on infants who declined to participate or who were excluded, so we are unable to comment on the impact of refusals or exclusions. Second, an observational study design with un-blinded quasi-randomised allocation process was chosen for practical reasons. Average TSB and age at commencement of treatment resulted imbalanced across the treatment arms, but they were included as confounders in all multivariable analyses. Finally, the study did not constrain clinical decisions about the distance of the bulb units from the infant, or their use of high and low intensity modes (options available in the single-sided machines). Although these aspects may have affected some observed differences between single- and double-sided phototherapy, our findings nevertheless demonstrated the advantages of double-sided high-intensity phototherapy in actual use in a real world LRS.

Conclusions {#sec021}
===========

We found no difference in the effectiveness of the two single-sided LED machines in terms of speed of reduction of TSB, duration of treatment or LOS in the NCU. Compared to single-sided machines, the double-sided machine showed a 45--54% increase in the rate of TSB reduction and a 14-hour reduction in both the duration of treatment and LOS in the NCU. Long-lasting LED phototherapy units eliminate the need for frequent replacement of bulbs, making it an affordable technology for LRSs and creating the opportunity for high quality phototherapy to be consistently provided. To maximise the benefit in terms of appropriateness of care and reduction in average patient load in the NCU and treatment of more infants on a single device, introduction of more effective phototherapy should be accompanied by review of standard practices of patient review and discharge to optimise the timing of treatment cessation and patient discharge.

Supporting information {#sec022}
======================

###### STROBE Research checklist.

(DOCX)

###### 

Click here for additional data file.

###### Dataset containing all data underlying the findings described in the manuscript.

(XLS)

###### 

Click here for additional data file.

The funding for the pilot project described in this study was provided by Eric Hemel and Barbara Morgen, donors to Thrive Networks, a no-profit international non-governmental organization (<https://thrivenetworks.org/>) headquartered in Oakland, California, USA, as well as a development grant from the Regione Trentino Alto Adige, Italy. The study was implemented by the Breath of Life Program, Thrive Networks, in full partnership with Amici della Neonatologia Trentina, Trento, Italy, which supported the involvement of some of the authors as consultants \[GA, LM\] and volunteers \[KM\]. THT was financially supported by the Da Nang Women and Children's Hospital, in her roles as director of the neonatal unit. Data was collected by many hospital staff. We gratefully acknowledge the contribution of donors and staff who, together, made this work possible.

AAP

:   American Academy of Pediatrics

BOL

:   Breath of Life Program

CI

:   Confidence Interval

IQR

:   Interquartile range (1st quartile, 3rd quartile)

INGO

:   International Non-Governmental Organization

LOS

:   Length of stay

LRS

:   Low resource setting

NCU

:   Neonatal Care Unit

OLS

:   Ordinary Least Squares Regression

TSB

:   Total Serum Bilirubin

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
